Dual-Faced Embroidery of AI in Healthcare: Navigating Certainty and Future Potential in Real-World Applications

Mar 20, 2025 10:45 CST Updated 10:45

微信图片_20250318102213.jpg As AI technology permeates the healthcare sector with revolutionary momentum, it presents a dual reality: on one side, a surge of capital enthusiasm and the inevitable wave of technological iteration; on the other, future-oriented challenges in scenario implementation and business models. This technological transformation resembles a “double-sided embroidery,” requiring both a solid industrial foundation to confirm the path forward and a forward-looking vision to anticipate the future.

At this critical juncture in the industry’s development, with“Through the Lens: The Certainty and Future of AI Healthcare’s [Double-Sided Embroidery] Scenario Implementation”The BT/IT series of events themed aroundThursday, March 27, 2:00 PMMint Café, 1st Floor, Bohe Innovation Center, Suzhou Industrial ParkGrand Opening! This event brings together top-tier investment institutions, leading AI healthcare companies, and industry experts, focusing on “Capital-Driven, Scenario Breakthroughs, Efficacy Validation“Three Key Dimensions: Deconstructing the Real Logic of AI in Healthcare from Technological Explosion to Value Realization, Providing Practitioners with the Most Practical Arena for Strategic Thinking.”

Event Overview

Event Theme:A Deep Dive: The Certainty and Future of AI Healthcare’s [Double-Sided Embroidery] Scenario Implementation

Event Duration:March 27 (Thursday) 14:00-17:00

Venue:Mint Café, 1st Floor, Suzhou Industrial Park Bohe Innovation Center

Hosted by:Bohe Innovation Center, VCBeat

Supporting Organizations:China Academy of Information and Communications Technology (Jiangsu) Institute of Technological Innovation, Digital Medical Technology Research Institute of Shanghai Yangtze River Delta Technology Innovation Research Institute

拼图.jpg

Event Value

We will bring:

1. Cross-Boundary Integration: Collision of Perspectives from Capital, Enterprises, Hospitals, and Regulators to Break the “Technology Silos” in AI Healthcare.

2. Practice-Oriented: Pop-up Product Showcases by Enterprises + Case Study Workshops on Scenario-Based Implementation, Directly Addressing Commercialization Pain Points.

3. Proactive Breakthroughs: The Evolution of Healthcare + AI Transformation and the Investment Landscape for Large Healthcare Models, Anticipating the Next Inflection Point in the Sector.

Event Agenda

活动议程(1)_01(1).png

Guest Introduction

Le Xiaotong

General Manager, Bohe Innovation Center

Master’s degree in Microbiology and Biochemical Pharmacy from China Pharmaceutical University, with over 15 years of experience in biopharmaceutical industrial parks, public service platforms, and startup incubation services. As a founding team member of BioBAY and BioTOP, and former Deputy General Manager of Baituo Biotech, he was fully responsible for establishing and standardizing the operation of a public technical service platform for chemical and biological analysis. He spearheaded the creation of Baituo Makerspace, BioBAY’s seed incubator, building it from the ground up; to date, it has signed more than 100 incubated projects, many of which have been recognized as leading talent initiatives at various levels, and the space has received national-level certification as a makerspace. In 2020, he joined Bohe, where he led the establishment of Adock (Bohe Innovation), an incubation and innovation center focused on the convergence of IT and BT (Information Technology and Biotechnology).

Yan Jingjing

Founding Partner, Probes Capital

14 years of experience in the healthcare industry and investment; founded Probe Capital in 2017

Since 2017, Yan Jingjing has led her team in assisting nearly 100 life sciences innovators with financing and M&A transactions, amounting to a cumulative total of over RMB 20 billion. The engagements span multiple sub-sectors, including innovative drugs, innovative medical devices, biotechnology, healthcare services, and digital health. Representative cases include Zhiyun Health, Jianhai Technology, StemRNA, CytoMed Therapeutics, Siduoke, Delutong, Bluepha, Huade Bio, Kanglu Biotech, Furen Shufan, and Tailai Biology.

Established the Probe New Healthcare Fund in 2020, which has invested in more than ten leading companies in the sector as of 2023, including Saifu Pharmaceuticals, Regal Bio, and PureDiag.

Yan Jingjing has actively promoted the digital transformation of investment industries. In 2022, she led her team to launch “Shennong No. 1,” the first investment-assisted decision-making platform in the healthcare and life sciences sector.

Mr. Yan Jingjing previously spearheaded the establishment of the investment department at VCBeat, serving as Investment Director, where he oversaw investor relations for the financial advisory (FA) business segment and the development of an enterprise innovation ecosystem network; he also participated in post-investment management for healthcare projects at Yueyin Investment.

Yang Zhiwen

Founding Partner, Nuoyu Capital

Partner, Yi Er San Technology Transfer Platform

Host of "Lao Yang's Casual Chat" Column

Zhang Ce

Senior Vice President, Jianhai Technology

Senior Expert in the Healthcare, Pharmaceutical, and Commercial Insurance Industries; Drove Strategic Upgrades and the Implementation of Innovative Business Initiatives for Multiple Companies;

Currently serving as Senior Vice President of Jianhai Technology, with overall responsibility for the company’s strategic upgrade and growth of innovative businesses;

Formerly served as

Vice President of Pharmaceutical Innovation at Ping An Health, responsible for the pharmaceutical operations management and strategic innovation in pharmaceutical commercial insurance business of Ping An Health Group;

Senior Vice President of Dingdang Kuaiyao Group, spearheaded the development of Dingdang’s internet medical services and commercial insurance business segments, facilitating the company’s completion of its Series B/B+ strategic financing.

Pan Shouxiang

CFO of Hangzhou Quanzhen Medicine

Master of Economics from Fudan University; formerly Vice President of Medical Investment at Hangzhou Kaitai Capital Management Co., Ltd. (2015–2021) and Deputy General Manager of Finance at Nanjing Shengde Medical Technology Co., Ltd. (2021–2023); currently Chief Financial Officer and Board Secretary at Hangzhou Quanzhen Medical Technology Co., Ltd., with overall responsibility for corporate finance and major external partnerships.

Zhang Kuan

CEO of Beizuo Health

Former Positions:

Attending Physician, Department of Cardiovascular Medicine, Grade 3A Hospital

President of WeDoctor Wuzhen Internet Hospital

General Manager, Strategic Investment, WeDoctor

Head of Hospital Ecosystem, Baidu Health Business Group

Dean, Baidu Health Internet Hospital

With 16 years of deep-rooted experience in the healthcare industry, we founded Beizuo Health alongside a group of like-minded young attending physicians from top-tier (Grade III Class A) hospitals and AI experts in the new era of artificial intelligence. Specializing in the integration of healthcare with large AI models, we are dedicated to developing high-quality products and services to provide intelligent cardiovascular and cerebrovascular healthcare solutions to countless families.

Cao Qun

Chairman of Xinjing Technology

Bachelor of Clinical Medicine, Zhejiang University School of Medicine; MBA, Zhejiang University School of Management. Formerly a cardiothoracic surgeon at a Grade 3A hospital, North and Northwest China Director at Tiancheng Pharmaceutical, East China Sales Director at Edan Instruments, and General Manager of Dingguo Technology. With over 30 years of experience in the healthcare industry, he founded Hangzhou Xinjing Technology Co., Ltd. in August 2016.

Wang Jun

Co-Founder of Weimei Health

Ph.D. in Computer Science, Peking University

Leading Talent in Science and Technology Entrepreneurship of Beijing

Vice Dean, Beijing Zhongke Amoeba Information Science Research Institute

With 15 years of experience in healthcare IT, I co-founded Weimei Health in 2021. Focused on the innovative application of AI in the medical field, we have provided digital hospital solutions to over 3,000 healthcare institutions by 2025, driving improvements in AI-enabled diagnostic and service capabilities at the primary care level. Weimei Health completed its angel round and Series A financing in 2022 and 2025, respectively.

He Jun

Researcher and Doctoral Supervisor, Jiangsu Provincial Institute of Hematology, The First Affiliated Hospital of Soochow University

Research interests primarily focus on HLA and molecular immunogenetics, as well as clinical and basic research in hematopoietic stem cell transplantation and organ transplantation. In recent years, he has presided over five General Program projects of the National Natural Science Foundation of China and a total of 23 projects, including special projects for clinical medical science and technology in Jiangsu Province. He has published 240 articles indexed by SCI or listed in core Chinese medical journals as the first or corresponding author. He has authored or participated in the formulation of 13 Chinese expert consensuses, guidelines, and group standards. He has received more than 20 scientific achievement awards, including the Ministry of Education and Jiangsu Provincial Science and Technology Progress Awards and the Jiangsu Provincial New Technology Introduction Award. He has obtained nine national invention patents and software copyrights. Under his leadership, the HLA typing laboratory became the first medical laboratory in China to simultaneously hold international ASHI accreditation (the first nationwide in 2011) and CNAS recognition, and it has served as the designated HLA high-resolution confirmatory typing laboratory for the China Marrow Donor Program for 19 consecutive years.

Zhang Yuming

Director of the Health and Medical Big Data and Network Research Center (East China), China Academy of Information and Communications Technology; Chief Engineer, Key Laboratory for Intelligent Medical Device Research and Evaluation, National Medical Products Administration

Biomedical Engineering major, Master of Business Administration (MBA). Formerly served as General Manager of the China Division of a Fortune 500 company, senior executive at a leading domestic medical device enterprise, and Senior Advisor to a national-level think tank.

With 30 years of dedicated focus on the medical device industry, possesses extensive experience in China market access, marketing, corporate management, strategic planning, and industry consulting. Closely monitors national policies on public health, researches the integration of next-generation communication technologies with the healthcare sector, and is committed to promoting the application of new technologies in the medical field. In particular, has in-depth research and practical experience in the innovative incubation, market access, commercial positioning, and business loop closure of products such as smart hospitals, digital health, medical AI, and intelligent medical devices.

Social Affiliations:

Vice President and Secretary-General of the Medical Engineering Professional Committee, China Association for Quality Inspection

Secretary-General, Branch on Digital-Intelligent Medical Equipment and Robotics, Chinese Society for Health Information and Big Data in Healthcare

Executive Deputy Secretary-General, Digital Therapeutics Professional Committee, China Association for the Promotion of Rehabilitation Technology Transformation and Development

Editorial Board Member of eHealth Clinical (ISSN: 2588-9141)

Editorial Board Member of Metaverse Medicine (ISSN: 3006-4236)

Member of the Clinical Engineering Branch, Chinese Association of Medical Equipment

Vice Chairman, China Chapter of the International Medical Information Integration Association

Note: The order of guests is based on their appearance sequence.

Company Profile

Hangzhou Quanzhen Medicine

Founded by Dr. Xue Chong, who holds a Ph.D. in Surgery from Peking Union Medical College, Chinese Academy of Medical Sciences, and completed postdoctoral research at Johns Hopkins University School of Medicine, the company was established in Binjiang, Hangzhou.

QuanZhen Medicine has long been committed to building an AI-driven medical research and application platform that integrates industry, academia, research, and clinical practice. The company’s independently developed QuanZhen Medical Large Language Model and generative AI products—the “QuanZhen Tong” series—are leading intelligent physician assistants deployed hospital-wide at dozens of large, comprehensive Grade 3A tertiary hospitals in China, placing QuanZhen Medicine among the top tier in the country for the number of hospital implementations of its medical large language models.

Xinjing Technology

Xinjing Technology was jointly established by multiple research institutions and experts, including the Second Xiangya Hospital of Central South University (National Clinical Research Center for Mental Disorders), Zhejiang Provincial Mental Health Center, and the Mental Health Center of Zhejiang University School of Medicine. As a national high-tech enterprise and a Zhejiang Province “Specialized, Refined, Differential, and Innovative” enterprise, it is the first to integrate advanced technologies such as VR and AI with cutting-edge therapeutic concepts and methods in modern clinical medicine. The company has obtained two Class II medical device registration certificates in China—the first of their kind—for the use of VR in the treatment of sleep disorders and cognitive impairments. Its product series have been included in relevant expert consensus statements, with its sleep-related products featured in the “Chinese Guidelines for the Diagnosis and Treatment of Insomnia Disorder.”

Beizuo Health

Beizuo Health is a digital and intelligent service provider specializing in cardiovascular and cerebrovascular health. We introduce globally leading smart medical devices and cutting-edge imaging equipment, and collaborate with top-tier domestic experts to build an intelligent healthcare platform. Leveraging our exceptional R&D capabilities in medical solutions and data-driven health intervention models, we provide member users with intelligent management of the “three highs” (hypertension, hyperglycemia, and hyperlipidemia), intelligent screening for cardiovascular and cerebrovascular risks, and comprehensive healthcare services. Our medical device supply chain features renowned brands such as Abbott, Siemens, GE, Huawei, Silicon Intelligence, and Omron.

The company is backed by Hangzhou State-owned Capital Funds, was selected for the Hangzhou High-Level Talent Innovation and Entrepreneurship Project in 2024, and holds multiple AI invention patents in the field of cardiovascular and cerebrovascular diseases.

Weimei Health

Weimei Health Technology (Beijing) Co., Ltd. is a technology innovation enterprise focused on the application of big data and artificial intelligence in the healthcare sector. As an advanced provider of AI-powered healthcare products and services, the company has mastered 92% of core AI technologies in the fields of computer vision, natural language processing, and knowledge graphs, and has established a professional knowledge system at the hundred-billion scale. It has launched the “Singularity MedQuery” large medical model platform, offering diversified products and services to the industry. Weimei Health aims to empower the sector through technology, accelerate the integration of AI with the real economy, drive the upgrading of the healthcare industry, and propel the industry into a truly intelligent era.

The company’s product portfolio includes medical AI solutions built on the “Qidian Yiwen” healthcare large language model platform, such as smart hospital information platforms, AI-powered pre-consultation triage, AI patient guidance, AI electronic medical record quality control systems, AI-assisted physician diagnostic platforms, and AI-driven hospital performance evaluation platforms. The company has established regional divisions in North China, Central China, Southwest China, Northwest China, and Northeast China to handle local sales and technical support. Founded in Beijing in 2021, the company is recognized as a “high-tech, frontier, and cutting-edge” technology enterprise in Zhongguancun. Its core technical team comprises graduates from top domestic and international institutions, including the Chinese Academy of Sciences, Tsinghua University, Peking University, the University of Science and Technology of China, and the University of Science and Technology Beijing, while its core management team hails from leading companies such as Alibaba, Tencent, Baidu, DXY, and Neusoft.

Introduction to the Organizer

Bohe Innovation Center

Adock, initiated by the Mint Angel Fund, is dedicated to becoming China’s first innovation incubation center at the intersection of Information Technology (IT) and Biotechnology (BT). By introducing and incubating life and health startups empowered by IT support, and supplemented by professional carrier platforms and robust scientific incubation services, Adock aims to build an innovative ecosystem characterized by cross-disciplinary integration.

VCBeat

VCBeat, founded in 2014, is an industry information acceleration service platform that builds a repository of industrial business cases through written content, deconstructs the industry through systematic research, and promotes industrial cooperation and connectivity through its services. It provides brand communication, research consulting, data monitoring, and resource/project matchmaking services to enterprises, government industrial parks, investment institutions, and other entities within the industry chain. Since its establishment, VCBeat has received investments from several well-known firms, including Legend Holdings’ Junlian Capital, Baidu Ventures (BV), Honghui Capital, Changling Capital, Yifang Group, and Weilai Capital under By-Health, achieving a valuation of hundreds of millions of RMB.

After 11 years of deep industry cultivation, the brand matrix has evolved from “VCBeat, VB100, VCBeat, and VCBeat Orange” to VCBeat, VBEF, and VBInsight.

Supporting Organizations

CAICT (Jiangsu) Institute of Technological Innovation

Suzhou New District Branch of China Academy of Information and Communications Technology (Jiangsu) Institute of Scientific and Technological Innovation Co., Ltd. was established on September 9, 2024. As the operating entity for the NMPA Key Laboratory of Intelligent Medical Device Research and Evaluation, it is an enterprise specializing in scientific research and technical services. The laboratory is led by the China Academy of Information and Communications Technology (CAICT) and jointly established with the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA). Focusing on three key areas—AI-enabled medical devices, mobile/remote medical devices, and network and data security for medical devices—the laboratory conducts research and consulting, standard development, inspection and testing, and experimental validation. By building internationally leading and domestically top-tier capabilities for full-lifecycle services of intelligent medical devices, the laboratory aims to address bottlenecks and challenges within the industrial chain, promote the translation and application of innovative achievements, and foster a new ecosystem for the intelligent medical device industry.

Shanghai Yangtze River Delta Institute of Technical Innovation, Institute of Digital Medical Technology

Shanghai Yangtze River Delta Institute of Technology, Digital Health Technology Research InstituteSupported vigorously by the Baoshan District of Shanghai, the Digital Health Technology Research Institute of the Shanghai Yangtze River Delta Institute of Technology is the first specialized research institute in the biopharmaceutical field established, cultivated, and developed by the Yangtze River Delta International Technology Innovation Center in Shanghai. Addressing critical public health needs, the institute conducts research on common key technologies across the entire digital healthcare chain, including prevention, diagnosis, treatment, rehabilitation, and health maintenance. It aims to accelerate the translation of clinical research outputs and achievements, foster new business models in data-driven healthcare management, clinical research, and traditional Chinese medicine (TCM) industry services, and thereby promote supply-side reform in medical services and the digital transformation of the TCM industry.

Event Registration Now Open

Scan the QR code above to register or contact Mr. Yang at VCBeat.

15360825131 (WeChat)